Nilutamide
Modify Date: 2025-08-22 23:49:20
Nilutamide structure
|
Common Name | Nilutamide | ||
|---|---|---|---|---|
| CAS Number | 63612-50-0 | Molecular Weight | 317.221 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C12H10F3N3O4 | Melting Point | 1490C | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS06, GHS08 |
Signal Word | Danger | |
Use of NilutamideNilutamide (Nilandron) is a non-steroidal anti-androgen drug proposed in the treatment of metastatic prostatic carcinoma[1][2]. |
| Name | nilutamide |
|---|---|
| Synonym | More Synonyms |
| Description | Nilutamide (Nilandron) is a non-steroidal anti-androgen drug proposed in the treatment of metastatic prostatic carcinoma[1][2]. |
|---|---|
| Related Catalog | |
| References |
[2]. Ask K, et al. Metabolism of nilutamide in rat lung. Biochem Pharmacol. 2006 Jan 12;71(3):377-85. |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Melting Point | 1490C |
| Molecular Formula | C12H10F3N3O4 |
| Molecular Weight | 317.221 |
| Exact Mass | 317.062347 |
| PSA | 95.23000 |
| LogP | 2.23 |
| Index of Refraction | 1.524 |
| InChIKey | XWXYUMMDTVBTOU-UHFFFAOYSA-N |
| SMILES | CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O |
| Storage condition | Store at RT |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS06, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H360 |
| Precautionary Statements | P201-P301 + P310-P308 + P313 |
| Personal Protective Equipment | Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | T:Toxic; |
| Risk Phrases | R60;R25 |
| Safety Phrases | 53-36/37/39-45 |
| RIDADR | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS | NI9453300 |
| HS Code | 2933990090 |
|
~%
Nilutamide CAS#:63612-50-0 |
| Literature: US2012/142937 A1, ; Page/Page column 7 ; |
| Precursor 1 | |
|---|---|
| DownStream 0 | |
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Phase I and phase II reductive metabolism simulation of nitro aromatic xenobiotics with electrochemistry coupled with high resolution mass spectrometry.
Anal. Bioanal. Chem 406(28) , 7253-60, (2014) Electrochemistry combined with (liquid chromatography) high resolution mass spectrometry was used to simulate the general reductive metabolism of three biologically important nitro aromatic molecules:... |
|
|
Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds.
J. Phys. Chem. B 118(33) , 9974-82, (2014) Amorphous forms of drugs are increasingly being used to deliver poorly water-soluble compounds. Therefore, understanding the magnitude and origin of differences in crystallization kinetics is highly i... |
|
|
High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.
Assay Drug Dev. Technol. 12(7) , 395-418, (2014) The androgen receptor-transcriptional intermediary factor 2 (AR-TIF2) positional protein-protein interaction (PPI) biosensor assay described herein combines physiologically relevant cell-based assays ... |
| MFCD00864670 |
| 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]- |
| Nilandron |
| Nilandrone |
| 5,5-Dimethyl-3-[4-nitro-3-(trifluormethyl)phenyl]imidazolidin-2,4-dion |
| 5,5-diméthyl-3-[4-nitro-3-(trifluorométhyl)phényl]imidazolidine-2,4-dione |
| Nilutamide |
| Anandron |
| 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione |
| Nilutamida |
| 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione |
| Nilutamidum |